Human epidermal growth factor receptor 2 (HER2)-positive breast cancer comprises a HER2-enriched subtype and luminal B subtypes (10–15%) in molecular profiling and is addicted to the HER2 oncogene; thus, HER2-targeted therapies combined with cytotoxic chemotherapy are regarded as the standard treatment. Here, ERBB2 is linked to breast carcinoma.